Pfizer board recommends ₹75 dividend for FY26

1 min read     Updated on 08 Jul 2026, 05:49 AM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Pfizer Limited reported a 10.4% rise in revenue to ₹2,520 crore for FY26 and recommended a final dividend of ₹75 per share. The 75th AGM is scheduled for July 28, 2026, via video conferencing, with the record date set for July 17, 2026.

powered bylight_fuzz_icon
44912124

*this image is generated using AI for illustrative purposes only.

Pfizer Limited has recommended a final dividend of ₹75 per equity share of ₹10 each for the financial year ended March 31, 2026. The company reported a 10.4% increase in revenue from operations to ₹2,520 crore, while profit after tax stood at ₹722.43 crore. The 75th Annual General Meeting is scheduled for July 28, 2026, through video conferencing.

The Board of Directors, at its meeting held on May 12, 2026, approved the dividend recommendation. The record date for determining shareholder eligibility is July 17, 2026. If approved at the AGM, the dividend will be paid on or after August 4, 2026.

Financial Highlights

Metric FY 2026 (₹ in crore) FY 2025 (₹ in crore)
Revenue from operations 2,519.65 2,281.35
Net sales 2,377.11 2,128.36
Profit before tax 975.67 1,016.09
Profit after tax 722.43 767.60
EBITDA margin 35.9% N/A

The remote e-voting period will commence on July 24, 2026, and end on July 27, 2026. The cut-off date for determining eligibility for voting is July 21, 2026. The company has appointed KFin Technologies Limited to facilitate the e-voting process.

AGM Agenda

The AGM will transact ordinary business, including the adoption of audited financial statements and the declaration of the final dividend. Special business includes the ratification of remuneration payable to M/s. Kishore Bhatia & Associates, Cost Accountants, for the financial year ending March 31, 2027. The remuneration is fixed at ₹11,00,000 plus applicable taxes and out-of-pocket expenses. The Board has also proposed the re-appointment of Mr. P. Rengan, Director liable to retire by rotation.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE182A01018/a70a18ac531143eb.pdf

Historical Stock Returns for Pfizer

1 Day5 Days1 Month6 Months1 Year5 Years
-0.06%+1.11%+7.47%+2.38%-2.84%-16.60%

What factors contributed to the decline in profit before tax despite the 10.4% revenue growth?

How does the company plan to sustain or improve its EBITDA margin in the upcoming fiscal year?

Will Pfizer Limited maintain its current dividend payout ratio given the slight dip in net profit?

US House Committee probes Pfizer, Eli Lilly, Bristol Myers on China trials

0 min read     Updated on 30 Jun 2026, 09:29 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

The US House Committee has sent letters to Pfizer, Eli Lilly, and Bristol Myers Squibb regarding their drug trials in China. The committee is probing the nature and execution of these clinical trials.

powered bylight_fuzz_icon
44380752

*this image is generated using AI for illustrative purposes only.

The US House Committee has sent letters to Pfizer , Eli Lilly, and Bristol Myers Squibb regarding their drug trials in China. The committee is probing the nature and execution of these clinical trials.

The letters seek detailed information from the pharmaceutical companies. This development highlights increased scrutiny on international clinical trial operations.

Historical Stock Returns for Pfizer

1 Day5 Days1 Month6 Months1 Year5 Years
-0.06%+1.11%+7.47%+2.38%-2.84%-16.60%

How might this scrutiny impact the timeline and approval process for drugs currently in clinical trials in China?

Could increased regulatory oversight lead to higher operational costs for pharmaceutical companies conducting international trials?

What potential legal or financial penalties could Pfizer, Eli Lilly, and Bristol Myers Squibb face if the investigation uncovers misconduct?

More News on Pfizer

1 Year Returns:-2.84%